Abstract: A novel pharmaceutical composition and method is disclosed for the treatment of cardiovascular diseases, e.g. myocardial ischemia and/or arrhythmia. The method and composition include an effective amount of a compound of the formula ##STR1## wherein X, Y, R, R.sub.1, A, A', m, n, p, p' and B are as defined herein.

Abstract: This process enables preparation of the preferred (+)-threo enantiomer by resolution of its racemic mixture of a compound of the formula ##STR1## wherein Y.sup.1 and Y.sup.2 are each independently lower alkyl and R.sup.1 is hydrogen or lower alkyl. The compound is treated with a chiral acid (tartaric aicd preferred) in an organic solvent (ethanol preferred) to yield the (+)-threo enantiomer, which is then recovered from the reaction mixture. This enantiomer may then be used to produce the preferred (+)-cis enantiomer of certain benzothiazepine cardiovascular agents.

Abstract: Novel compounds of the formula ##STR1## exhibit calcium channel blocking activity and are useful as cardiovascular agents.

Abstract: Vasodilating activity is exhibited by compounds having the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein X is --CH.sub.2 -- or --S--;R.sub.1 is ##STR2## or --O--Y.sub.3 ; R.sub.2 is heterocyclo or heteroaryl;R.sub.3 and R.sub.4 are each independently hydrogen, halogen, alkyl, alkoxy, aryloxy, arylalkoxy, arylalkyl, cyano, hydroxy, alkanoyloxy, ##STR3## fluoro-substituted alkoxy, fluoro-substituted alkyl, (cycloalkyl)alkoxy, --NO.sub.2, --NY.sub.10 Y.sub.11, --S(O).sub.k alkyl, --S(O).sub.k aryl ##STR4## n is 0, 1, 2 or 3; m is 0, 1, 2 or 3;k is 0, 1 or 2;Y.sub.1 and Y.sub.2 are each independently hydrogen or alkyl; or Y.sub.1 is hydrogen and Y.sub.2 is alkenyl, alkynyl, aryl, heteroaryl, or cycloalkyl; or Y.sub.1 and Y.sub.2, together with the carbon atom to which they are attached, are cycloalkyl;Y.sub.3 is hydrogen, alkyl, alkanoyl, alkenyl, arylcarbonyl, heteroarylcarbonyl, or ##STR5## Y.sub.8 and Y.sub.9 are each independently hydrogen, alkyl, aryl, or heteroaryl; or Y.sub.

Abstract: Vasodilating activity is exhibited by compounds having the formula ##STR1## wherein X can be --S--or --CH.sub.2 --; andR.sub.2 is ##STR2##depending upon the definition of X.

Abstract: Vasodilating activity is exhibited by compounds having the formula ##STR1## and pharmaceutically acceptable salts thereof.

Abstract: Vasodilating activity is exhibited by compounds having the formula ##STR1## and pharmaceutically acceptable salts thereof.

Abstract: Spiro compounds of the formula ##STR1## wherein X is oxygen or sulfur. These compounds possess antgiotensin converting enzyme inhibition activity and are thus useful as anti-hypertension agents.

Abstract: Vasodilating activity is exhibited by compounds having the formula ##STR1## n is 2 or 3; X is oxygen or sulfur;R.sub.1 and R.sub.2 are each independently hydrogen alkyl, cycloalkyl, or allyl, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl, or morpholinyl;R.sub.3 is alkyl, alkoxy, halogen, trifluoromethyl, or nitro;R.sub.4 is hydrogen, halogen, trifluoromethyl, or nitro; andR.sub.5 and R.sub.6 are each independently alkyl or cycloalkyl or R.sub.5 and R.sub.6 together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl, or morpholinyl.

Abstract: Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids are useful for the treatment of hypertension.

Abstract: Compounds of the formula ##STR1## are useful as intermediates in the preparation of various hypotensive agents.

Abstract: Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids are useful for the treatment of hypertension.

Abstract: Hypotensive activity is exhibited by compounds having the formula ##STR1## and salts thereof wherein R.sub.1 is alkyl, aryl, arylalkyl, cycloalkyl, or cycloalkylalkyl;R.sub.2 is cycloalkyl, 3-cyclohexenyl or 2-alkyl-3-cyclohexenyl;R.sub.3 is alkyl, cycloalkyl, phenyl or alkoxy;R.sub.4 is hydrogen or alkyl;one of R.sub.5 and R.sub.6 is hydrogen and the other is alkyl-X-, phenyl-X-, alkoxy, phenyloxy, phenyl, cycloalkyl, alkyl, or phenylalkyl; or together R.sub.5 and R.sub.6 are --XCH.sub.2 CH.sub.2 X--;R.sub.7 is hydrogen or ##STR2## and n is 0 or 1.

Abstract: Carboxyalkyl dipeptides of the formula ##STR1## wherein R.sub.4 is a 3-, 4-, 5-, or 4,4-substituted proline are disclosed. These compounds are useful as hypotensive agents due to their angiotensin converting enzyme inhibition activity.

Abstract: Compounds of the formula ##STR1## are useful as intermediates in the preparation of various hypotensive agents.

Abstract: Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids are useful for the treatment of hypertension.

Abstract: This invention is directed to compounds of the formula ##STR1## and various intermediates therefore. The final products possess useful hypotensive activity.

Abstract: This invention is directed to compounds of the formula ##STR1## and various intermediates therefore. The final products possess useful hypotensive activity.

Abstract: New mercaptoacyl derivatives of substituted prolines which have the general formula ##STR1## are useful as hypotensive agents.

Abstract: Vasodilating activity is exhibited by compounds having the formula ##STR1## n is 2 or 3; X is oxygen or sulfur,R.sub.1 and R.sub.2 are each independently hydrogen alkyl, cycloalkyl, or allyl, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl, or morpholinyl;R.sub.3 is alkyl, alkoxy, halogen, trifluoromethyl, or nitro;R.sub.4 is hydrogen, halogen, trifluoromethyl, or nitro; andR.sub.5 and R.sub.6 are each independently alkyl or cycloalkyl or R.sub.5 and R.sub.6 together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl, or morpholinyl.